Tissue microarrays for rapid linking of molecular changes to clinical endpoints.

摘要: Advances in genomics and proteomics are dramatically increasing the need to evaluate large numbers of molecular targets for their diagnostic, predictive or prognostic value clinical oncology. Conventional pathology techniques often tedious, time-consuming, require a lot tissue, thereby limiting both number tissues that can be evaluated. Here, we demonstrate power our recently described tissue microarray (TMA) technology analyzing markers series 553 breast carcinomas. Four independent TMAs were constructed by acquiring 0.6 mm biopsies from one central three peripheral regions each formalin-fixed paraffin embedded tumors. Immunostaining TMA sections conventional "large" performed two well- established markers, estrogen receptor (ER) progesterone (PR), as well p53, another frequently examined protein which data on utility cancer less unequivocal. Compared with section analysis, single sample tumor identified about 95% information ER, 75 81% PR, 70 74% p53. However, all 12 analyses (three antibodies four different arrays) yielded significant more associations tumor-specific survival than (p < 0.0015 comparisons). A was sufficient identify between alterations outcome. It is concluded that, contrary expectations, heterogeneity did not negatively influence results. will substantial rapidly translating genomic applications.